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ABSTRACT
Dermal neurofibromas (DNFs) are benign peripheral nerve sheath tumors 
thought to originate from Schwann cell progenitors. These tumors represent one of 
the hallmarks of the neurofibromatosis type 1 (NF1) tumor predisposition syndrome, 
where they can number in the thousands. While NF1-DNFs arise due to mutations 
in the NF1 gene, the vast majority of DNFs occur sporadically (sp-DNFs), where the 
genetic etiology is currently unknown. Herein, we employed whole-exome sequencing 
of sp-DNFs to identify a recurrent mutation in the KIR2DL5 gene, which codes for a 
protein suppressor of natural killer (NK) cell activity. While the function of KIR2DL5 
outside of the immune system is unknown, we identified a KIR2DL5N173D mutation in 
three of nine sp-DNFs, resulting in loss of KIR2DL5 protein expression. In contrast, two 
of these subjects had unrelated tumors, which retained KIR2DL5 protein expression. 
Moreover, loss of KIR2DL5 expression was demonstrated in 15 of 45 independently-
identified sp-DNFs. Consistent with its potential role as a negative growth regulator 
important for neurofibroma maintenance, ectopic KIR2DL5N173D expression in normal 
human Schwann cells resulted in reduced KIR2DL5 expression and increased cell 
proliferation. Similarly, KIR2DL5 short hairpin RNA knockdown (KD) decreased 
KIR2DL5 protein levels and increased cell proliferation, as well as correlated with 
PDGFRβ and downstream RAS/AKT/mTOR hyperactivation. Importantly, inhibition 
of PDGFRβ or AKT/mTOR activity in KIR2DL5-KD human Schwann cells reduced 
proliferation to control levels. Collectively, these findings establish KIR2DL5 as a new 
Schwann cell growth regulator relevant to sp-DNF pathogenesis, which links sporadic 
and NF1-associated DNFs through RAS pathway hyperactivation.
INTRODUCTION
Dermal neurofibromas (DNFs) are common low-
grade peripheral nerve sheath tumors [1], which are 
hypothesized to arise from Schwann cell progenitors 
[2–4]. While these tumors do not undergo malignant 
transformation, they can be painful or number 
in the thousands, as seen in some adults with the 
neurofibromatosis type 1 (NF1; OMIM: 613113) cancer 
predisposition syndrome.  Nearly all adults with NF1 
manifest DNFs, which result from bi-allelic inactivation 
of the NF1 tumor suppressor gene and loss of NF1 
protein (neurofibromin) expression [5–7]. This bi-allelic 
NF1 loss reflects a combination of a germline NF1 gene 
mutation and the acquisition of a somatic NF1 mutation 
in Schwann cell lineage populations [3, 4]. As a RAS-
GTPase-activating protein (RAS-GAP), neurofibromin 
loss in Schwann cells leads to increased RAS activation 
[8–10] and downstream mechanistic target of rapamycin 
(mTOR)-mediated hyperproliferation [11–14]. 
While NF1 mutations characterize NF1-DNFs, the 
majority of DNFs occurs in the absence of NF1. These 
sporadic DNFs (sp-DNFs) are histologically identical to 
their NF1-associated counterparts, and most often arise as 
solitary dermal tumors. Since these tumors are encountered 
in individuals lacking other features supportive of a 
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clinical diagnosis of NF1, they do not harbor NF1 gene 
mutations. As such, it is currently not known what genetic 
mutations are responsible for the genesis of sp-DNFs. In 
an effort to identify potential molecular etiologies for these 
non-syndromal benign nerve sheath tumors, we performed 
whole exome sequencing on a series of NF1-associated 
and sporadic dermal neurofibromas. 
RESULTS AND DISCUSSION
In order to identify potential molecular etiologies 
for sporadic DNFs (sp-DNFs), we examined a cohort 
of 17 male patients (7 NF1-DNFs and 10 sp-DNFs) by 
whole-exome sequencing. Using this approach, NF1 
gene mutations were detected in 5/7 NF1-DNFs, and 
surprisingly, 1/10 (Sp7) sp-DNFs where the identified 
point mutation is predicted to result in a splicing variant 
of the NF1 transcript (Figure 1A, 1B). The inability 
to detect mutations in two of the NF1-DNFs likely 
reflects the insensitivity of exome sequencing to identify 
intronic mutations or large-gene deletions, both common 
mutational types in NF1 [15, 16]. However, consistent with 
a clinical diagnosis of NF1 or the presence of a NF1 gene 
mutation, immunohistochemical staining   confirmed loss 
of neurofibromin expression in the Sp7 tumor and in all 
NF1-DNFs (Figure 1C, Supplementary Figure 1). Subject 
Sp7 was lost to follow-up, and may have undiagnosed 
NF1 or harbored a tumor that underwent bi-allelic NF1 
gene inactivation [17]. Conversely, all sp-DNFs without an 
identified NF1 mutation, as well as an independent cohort 
of 45 unrelated sp-DNFs retain neurofibromin expression 
(Supplementary Figure 1), consistent with exclusion of 
NF1 as a clinical diagnosis.
While 105 genes with exonic nucleotide variations 
(frameshift insertions/deletions, missense, and nonsense 
mutations; Supplementary Table 1) were identified in more 
than one DNF, eight genes were mutated in at least four 
DNFs (> 22.22% of the cohort; Figure 1D, Supplementary 
Figure 2). These mutated genes did not separate sporadic 
or NF1-associated DNFs into clear subgroups; however, 
the specific nucleotide alterations identified in 6 of the 8 
genes were identical in all of the tumors examined (Figure 
1E). Importantly, three of these mutations have also been 
reported in other cancers (cBioPortal; www.cbioportal.
org), suggesting potential importance in DNF pathogenesis 
that could be pursued beyond the scope of this study.
While no mutations were found in genes commonly 
mutated in a related peripheral nerve sheath tumor 
(schwannoma; NF2 [18, 19], LZTR1 [20, 21], SMARCB1 
[22, 23] genes), recurrent mutations in the KIR2DL5 gene 
were identified only in the sp-DNFs (three of nine sp-DNFs 
examined). KIR2DL5 is a gene unique to primates, and is 
not found in cattle or mice [24]. Of note, the particular 
KIR2DL5 mutation (Asn173Asp, N173D; 3/9 tumors) 
resulted in a non-conservative change in an evolutionarily-
conserved residue (Figure 2A) within a predicted 
immunoglobulin-like domain [25] (Supplementary 
Figure 3A). In the three KIR2DL5N173D-mutant sp-DNFs, 
immunohistochemistry revealed no appreciable KIR2DL5 
protein expression, whereas human tonsil, normal human 
sural nerve, and all NF1-DNFs examined expressed 
KIR2DL5 (Figure 2B). To determine whether loss of 
KIR2DL5 protein expression correlated with the presence 
of a KIR2DL5N173D mutation, we examined two unrelated 
tumors (Sp5: basal cell carcinoma, Sp6: keratinous 
cyst) isolated from two of the three subjects with this 
mutation in their DNFs (Figure 2B). Both non-DNF 
tissues were immunopositive for KIR2DL5, suggesting 
that KIR2DL5N173D is likely a DNF-specific mutation. 
Moreover, in an independent cohort of sp-DNFs, 15/45 
tumors were KIR2DL5-immunonegative (33%; Figure 
2B, Supplementary Figure 3B), further supporting the 
hypothesis that KIR2DL5 expression loss is specific to sp-
DNFs and likely is caused by the KIR2DL5N173D mutation.
To determine whether the KIR2DL5N173D mutation 
was responsible for the reduction in KIR2DL5 protein 
expression observed, normal human Schwann cells were 
infected with either KIR2DL5WT or KIR2DL5N173D viral 
expression constructs (Figure 2D). Whereas wild-type 
KIR2DL5 expression was easily detected by Western blot 
and promoted a minor increase in Schwann cell growth 
(1.18-fold increase compared to PLKO-infected Schwann 
cells), KIR2DL5N173D mutant-expressing cells exhibited 
a 36.9% decrease in KIR2DL5 expression, a 1.88-
fold increase in cell proliferation (BrdU incorporation) 
(Figure 2E), and a 1.5-fold increase in total cell numbers 
(Figure 2F) relative to KIR2DL5WT expressing cells. 
Together, these data demonstrate that the KIR2DL5N173D 
mutation functions in a dominant negative manner to 
regulate KIR2DL5 expression and Schwann cell growth.
KIRs were initially discovered on the surface of 
natural killer (NK) cells [26], where they have been reported 
to mediate the immune response of NK cells and a subset of 
T lymphocytes against infection and cancer [27–29]. While 
KIR2DL5 is an orphan receptor with no known ligands, 
its phosphorylation in NK cells recruits the Src homology 
region 2-containing protein tyrosine phosphatase-2 
(SHP-2) molecule, resulting in activation of downstream 
signaling pathways. Since the role of KIR2DL5 has not 
been previously explored in non-immune system cells, we 
first demonstrated that KIR2DL5 is expressed in S100β+ 
Schwann cells within normal human peripheral (sural) 
nerve by immunofluorescence (Figure 2C), and in normal 
human Schwann cells by western blot (CTL; Figure 2D) 
and immunofluorescence (Supplementary Figure 4A). 
While the majority of the KIR2DL5 expression in both 
normal sural nerve and immunopositive sDNFs was found 
in the Schwann cell compartment, there was also expression 
in other cell types. In this regard, co-labelling of KIR2DL5+ 
cells with mast cell (tryptase, c-Kit) and fibroblast 
(vimentin)-specific antibodies (Supplementary Figure 4) 
revealed that the few remaining KIR2DL5-immunoreactive 
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cells in the Sp4, Sp5 and Sp6 DNF tumor specimens were 
stromal elements. 
As a complementary approach to expressing 
the mutant KIR2DL5 gene in normal human Schwann 
cells to reduce KIR2DL5 expression, endogenous 
KIR2DL5 expression was also decreased by RNA 
(shRNA) interference. Since KIR2DL5 is encoded 
by two genes, KIR2DL5A (OMIM: 605305) and 
KIR2DL5B (OMIM: 615727) that are > 99% sequence 
identical [25], three independently-generated short-
Figure 1: NF1 gene mutation and neurofibromin expression stratify DNFs into two subgroups. (A) List of detected NF1 
gene mutations and predicted protein alterations. (B) Schematic representation of NF1 gene mutations. (C) Representative images depicting 
decreased neurofibromin expression in tumors with NF1 mutations compared to sp-DNFs. Scale bar, 25 µm. (D) Genes recurrently mutated 
in more than four DNFs. (E)  Recurrent mutations identified in more than four DNFs. Black boxes = mutation. 
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hairpin RNA molecules were employed to target both 
genes.   Following Schwann cell infection, 76.78% 
(sh#1; TCTCTCCATGACTCACCCTAT), 88.29% 
(sh#2; CAGGAGCTCATTTGACATGTA) and 76.32% 
(sh#3; GAAACTCTTCAAGTAGTTCAT) KIR2DL5 
knockdown was achieved (Figure 3A), leading to 2.2, 
3.2- and 2.7-fold increases in cell number, respectively 
(direct cell counting; Figure 3B) relative to GFP-vector-
infected cells (CTL). This increase in cell numbers 
represented a 2.7- (sh#1), 2.83- (sh#2), and 3- (sh#3) 
fold increase in proliferation (BrdU incorporation; Figure 
3C), with no change in apoptosis (TUNEL staining; 
Figure 2: KIR2DL5N173D mutation reduces KIR2DL5 expression. (A) 3/9 sp-DNFs harbor the KIR2DL5N173D mutation. (B) 
KIR2DL5 mutation is associated with decreased KIR2DL5 protein levels in sp-DNFs but not NF1-DNFs or non-DNF tissue. Tonsil and sural 
nerve (S.N.) were used as controls. (C) KIR2DL5N173D expression results in reduced KIR2DL5 levels, as demonstrated with a myc antibody 
immunoblot of human Schwann cells infected with a myc-tagged KIR2DL5 WT or a KIR2DL5 N173D construct. KIR2DL5N173D expression 
results in increased (D) cell proliferation and (E) cell number relative to KIR2DL5WT control-infected Schwann cells. PLKO-GFP-control 
(PLKO)-infected cells are shown for comparison. Data are represented as means of three independent infections/over-expression construct 
± s.e.m. One-way ANOVA was used for statistical analysis. *p < 0.05; ***p < 0.001. Scale bar 50 μm.
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Supplementary Figure 3C). Expression of control 
KIR2DL5 engineered so as not to be targeted by these 
shRNA constructs following shRNA knockdown restored 
KIR2DL5 expression, as well as cell proliferation and 
cell numbers (Supplementary Figure 3D–3F).
Since RAS-dependent signaling is enhanced in NF1-
DNFs, the activation status of RAS (RAS-GTP) and RAS-
regulated pathways were examined. Following KIR2DL5 
knockdown (KIR2DL5A/BKD), there was a 3.5- (sh#1), 4.7- 
(sh#2), and 2.9- (sh#3) fold increase in RAS activation 
(RAS-GTP; Figure 4A). While others have shown that 
NF1-DNF growth depends on ERK1/2 pathway activation 
[30, 31], KIR2DL5 reduction had no effect on ERK1/2Thr202/
Tyr204 phosphorylation (activation; Supplementary Figure 
5A–5D), but rather led to increased AKT activation 
(AKTThr308 and AKTSer473 phosphorylation; sh#1, 31.5-fold 
and 2.8-fold; sh#2, 19.6-fold and 5.9-fold; sh#3, 15.6-
fold and 7.3-fold, respectively; n = 3), as well as elevated 
mTOR activation (S6Ser240/244 phosphorylation; sh#1, 3.2-
fold; sh#2, 4.9-fold; sh#3, 7.2-fold; n = 3) (Figure 4A). 
Similarly, expression of the mutant KIR2DL5 protein 
(KIR2DL5 N173D) resulted in 2.24-fold and 1.78-fold 
increases in AKT and S6 phosphorylation, respectively 
(Supplementary Figure 3). 
To demonstrate that KIR2DL5 regulates cell 
proliferation in an AKT/mTOR-dependent fashion, we 
initially employed an AKT-specific inhibitor (MK2206). 
Following a 4h MK2206 treatment of control- and 
shRNA-infected Schwann cells, AKTSer473 phosphorylation 
(sh#1, 0.9; sh#2 0.95; sh#3 0.97-fold), as well as the 
phosphorylation of two of its downstream effectors S6 
(sh#1, 0.4; sh#2 0.6; sh#3 0.5-fold) and PRAS40 (sh#1, 
Figure 3: KIR2DL5 is a negative Schwann cell growth regulator. (A) Co-localization of KIR2DL5 with S100β+ Schwann cells 
in normal human sural nerve. b. shRNA silencing of KIR2DL5A/B expression in normal human Schwann cells, where KIR2DL5A/BKD cell 
KIR2DL5 expression levels were calculated by normalizing the relative KIR2DL5/α-tubulin band intensity ratio to that of GFP-control-
infected Schwann cells. (B) western blot). KIR2DL5A/BKD results in increased (C) cell number and (D) proliferation relative to GFP-
infected serum-starved Schwann cells. Data are represented as means of three independent infections/shRNA construct ± s.e.m. One-way 
ANOVA with Bonferroni correction was used for statistical analysis. ***p < 0.001. Scale bar 25 μm.
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0.7; sh#2, 1.3; sh#3, 1.2-fold), were reduced to control 
levels (Figure 4B). Additionally, AKT inhibition restored 
cell numbers (Figure 4C) and proliferation (Figure 4D) 
to normal levels. Next, to determine whether mTOR 
inhibition could similarly reverse the effects of KIR2DL5 
KD, shRNA-infected Schwann cells were treated with 
rapamycin for 4h. Following rapamycin exposure, there 
was reduced AKTSer473 phosphorylation (sh#1, 0.7; sh#2 
1.1; sh#3 1.2-fold) and S6 phosphorylation (sh#1, 0.8; 
sh#2 0.8; sh#3 0.8-fold) (Supplementary Figure 5E), 
as well as restoration of cell numbers (Figure 4E) and 
proliferation (Figure 4F) to control levels. Collectively, 
Figure 4: KIR2DL5A/B is a negative regulator of RAS/AKT signaling. (A) shRNA silencing of KIR2DL5A/B in human Schwann 
cells results in increased RAS activity (RAS-GTP), as well as increased AKTThr308 , AKTSer473, and S6Ser240/244, but not ERK1/2Thr202/Tyr204, 
phosphorylation relative to GFP-infected Schwann cells. (B) AKTSer473, S6Ser240/244 and PRAS40Thr246 phosphorylation is restored to wild-type 
levels following MK2206 treatment of KIR2DL5A/BKD Schwann cells. 4 h MK2206 (C–D) or rapamycin (E–F) treatment restores (C, E) 
cell number and (D, F) proliferation of KIR2DL5A/BKD Schwann cells relative to GFP-infected controls. Experiments were repeated at least 
three times using independently-derived cell lysates. Data are represented as means ± s.e.m. Two-way ANOVA with Bonferroni correction 
was used for statistical analysis. ***p < 0.001.
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these data establish that KIR2DL5-regulated Schwann 
cell growth activates RTK/AKT/mTOR signaling, raising 
the intriguing possibility that Sp-DNFs and NF1-DNFs 
converge on hyperactivation of the same mitogenic 
signaling pathway.
RAS/AKT signaling is typically initiated by receptor 
tyrosine kinase (RTK) receptor engagement in Schwann 
cells [32–36]. In order to identify this hyperactivated 
RTK, a commercially-available human phospho-RTK 
array was employed, which recognizes 49 distinct 
RTKs (Figure 5A). Whereas the activity of most RTKs 
was not significantly altered (n = 48 RTK moieties), 
platelet-derived growth factor receptor beta (PDGFRβ) 
phosphorylation was elevated (sh#1, 3.5-; sh#2 3.9-; sh#3, 
3.5-fold) in KIR2DL5A/BKD Schwann cells relative to 
controls. Independent validation of two of these activation-
specific phosphorylation sites (PDGFRβTyr771: sh#1, 2-; 
sh#2, 4.5-; sh#3, 7.7-fold; and PDGFRβTyr1009: sh#1, 2-; 
sh#2, 5.4-; sh#3, 7.3-fold) confirmed receptor activation 
in KIR2DL5A/BKD Schwann cells (Figure 5B). Consistent 
with a dominant mechanism of action of the KIR2DL5 
N173D mutation, there was a 1.84-fold activation of 
PDGFRβ in KIR2DL5 N173D-expressing Schwann cells 
(Supplementary Figure 3). To determine the necessity 
of PDGFRβ activation for KIR2DL5A/BKD-mediated 
Schwann cell growth, we employed two different tyrosine 
kinase inhibitors that target PDGFRβ activation (imatinib 
[37–42] and sunitinib [43]), both of which are currently 
in clinical trials for the treatment of NF1-plexiform 
neurofibromas (Figure 5C–5F). Incubation of KIR2DL5A/
BKD Schwann cells for 16h with either inhibitor reduced 
PDGFRβ and AKT hyperactivation (Figure 5C–5D), as 
well as restored total cell numbers (Figure 5E) and cell 
proliferation (Figure 5F) to control levels.
While increased PDGFRβ activation was 
responsible for AKT-mediated hyperproliferation 
following KIR2DL5 loss, the mechanism by which 
KIR2DL5 regulates PDGFRβ is not clear. We hypothesize 
that KIR2DL5 binds PDGFRβ to restrict its activation. 
Consistent with this model, KIR2DL5 binds PDGFRβ 
in normal human Schwann cells by PDGFRβ antibody-
mediated immunoprecipitation. This binding is 
ameliorated in KIR2DL5A/BKD Schwann cells, resulting 
in a 7.8-fold increase in PDGFRβ binding to PDGFRα 
(sh#1, 5.2- ; sh#2, 9.6- ; sh#3, 8.7-fold increase; Figure 
5G). As such, KIR2DL5 likely inhibits PDGFRβ through 
direct binding, which reduces PDGFR heterodimerization, 
PDGFRβ phosphorylation and downstream RAS/AKT-
mediated Schwann cell growth (Figure 5H).  
Taken together, we identified the first mutation 
associated with sp-DNFs. This KIR2DL5 N173D mutation 
is hypothesized to result in attenuated KIR2DL5 protein 
levels, and as such, KIR2DL5 functions as a negative 
regulator of Schwann cell proliferation. In this regard, 
KIR2DL5 reduction, resulting either from KIR2DL5 
knockdown or KIR2DL5 N173D mutation, increases 
Schwann cell growth in a PDGFR/AKT/mTOR-dependent 
mechanism. Moreover, these studies provide the first 
demonstration that KIR2DL5 can function outside the 
immune system. Finally, while the etiologic mechanisms 
underlying sp-DNF and NF1-DNF growth control are 
distinct, they share a common signaling pathway amenable 
to therapeutic targeting.
MATERIALS AND METHODS
Tissue collection and processing
De-identified 10µm-thick sections of formalin-
fixed paraffin-embedded DNF tissue from 7 male patients 
with a confirmed NF1 diagnosis and from 10 male 
patients with sp-DNFs were collected from Washington 
University Surgical Pathology Department. Total genomic 
DNA was extracted following review by an experienced 
neuropathologist (S.D.) using a QIAamp DNA FFPE 
Tissue Kit (QIAGEN) following manufacturer’s 
instructions. Genomic DNA resuspended in elution 
buffer was sent for exome sequencing. Since this study 
was performed using de-identified dermal neurofibroma 
specimens and the patients could not be re-consented, 
we were unable to obtain blood for constitutional DNA 
analysis.
Whole-exome sequencing and filtering
Whole human exome sequencing was performed 
from total genomic DNA of 17 tumors by Otogenetics 
Co. Briefly, library preparation was performed using an 
Illumina platform. Pair-ended sequencing (100 bp) with 
a minimum average coverage of 30x or ~2.7–3Gb was 
performed on a HiSeq2500 platform (human exome V5). 
Sequence reads were mapped to human reference genome 
hg18. Variants were annotated in Annovar and were 
filtered in Microsoft Excel to include only the following 
criteria: (1) Exonic variations (2) Non-synonymous 
variations, stop loss/ stop gain, frameshift insertions 
and frameshift deletions (3) 1000 genome, ExAc and 
ESP6500 frequencies ≤ 0.01 (4) Deleterious variants 
according to SIFT, Polyphen and CADD predictions (5) 
Non-common polymorphism in Cosmic and ClinVar 
(Supplementary Table 1). Genes mutated more than 
twice per tumor or resulting in conservative amino acid 
changes were eliminated from further analysis. cBioPortal 
for Cancer Genomics (www.cbioportal.org) was used to 
search recurrent identified mutations in other cancers. The 
complete exome sequencing data is in the process of being 
uploaded to dbGaP. The sequence reads were as follows:
Sample Size Reads
Sp1 1,016,288,144 9,587,624
Sp2  2,980,285,61 28,115,902
Sp3  4,023,566,444 37,958,174
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Sp4  2,015,092,012 19,010,302
Sp5  2,763,643,024 26,072,104
Sp6  2,264,326,420  21,361,570
Sp7  3,049,257,056 28,766,576
Sp8 2,111,053,38 19,915,598
Sp9  850,889,772 8,027,262







NF1-7  2,751,629,620 25,958,770
Immunohistochemistry and immunofluorescence
Paraffin-embedded tonsil, 4 normal peripheral 
nerves (sural nerve), 23 NF1-DNFs (13 males, 10 
females) and 55 sp-DNFs (31 males, 24 females) were 
included in the immunohistochemical analyses. All 
DNFs were incubated with neurofibromin (Santa Cruz 
sc-67) antibodies, while and all DNFs, tonsil and normal 
sural nerve sections were incubated with KIR2DL5 
(Abcam; ab175895) antibodies. Biotinylated secondary 
rabbit antibodies (Vector Laboratories) were used in 
combination with Vectastain Elite ABC development 
and hematoxylin counterstaining. Normal human 
tonsil was used as the reference control tissue for the 
KIR2DL5 antibody. Images were acquired on a Nikon 
Eclipse E600 microscope conjugated with a Nikon 
Plan Fluor 10x/0.30 DIC L objective and a Leica EC3 
camera. Normal human sural nerve, sp-DNF sections, 
as well as primary cell cultures of normal human 
Schwann cells and HEK293T cells were analyzed by 
immunofluorescence using S100β (Millipore CB1040), 
c-Kit (Millipore; MAB1164), tryptase (Abcam; ab2378), 
vimentin (DSHB; AMF-17b) and KIR2DL5 (Abcam; 
ab129751) antibodies conjugated to appropriate Alexa 
Fluor secondary antibodies.  Images were acquired 
on a Nikon Eclipse TE300 fluorescence microscope 
conjugated with a Nikon Plan Fluor 20x/0.45 ELWD 
objective and a Leica DFC3000G camera. 
Normal human Schwann cell culture, lentiviral 
infection and pharmacological inhibitor 
treatments
Normal human Schwann cells (ScienCell Research 
Laboratories) were cultured on poly-L-lysine-coated plates 
in Schwann cell medium (ScienCell #1701) supplemented 
with Schwann cell growth factors, Pen/Strep and fetal 
bovine serum (FBS), unless otherwise stated and were 
maintained as per the manufacturer’s instructions. For 
serum-starvation experiments (Supplementary Figure 5), 
Schwann cells were plated on poly-L-lysine-coated plates 
in the presence of serum (FBS) for 16h, followed by a 36h 
period of serum deprivation during which cells were cultured 
only in Schwann cell medium supplemented with Schwann 
cell growth factors and Pen/Strep. 10% FBS was added to 
the cells for 2, 5, 15, 30 or 60 minutes at which time points 
cells were collected for  western blotting analysis. 
Three sets of lentiviral infection experiments were 
performed. Schwann cells were either infected once with 
lentivirus particles encoding (1) either a KIR2DL5WT 
control or KIR2DL5N173D to establish the effect of the 
identified mutation on normal Schwann cells (Figure 2), 
(2) either a GFP-control or shKIR2DL5 RNA to knock 
down KIR2DL5 expression (Figures 3–5), or were infected 
twice with lentiviral preparations encoding (3) both a 
GFP control and KIR2DL5CTL control or both shKRI2DL5 
RNA and KIR2DL5CTL to confirm the specificity of the 
shKIR2DL5 RNA constructs (Supplementary Figure 4). 
For all lentiviral infections, HEK-293T cells were initially 
cultured in DMEM (Gibco) supplemented with 10% 
heat-inactivated FBS and 1% Pen/Strep solution (Gibco). 
Three micrograms of total DNA was transfected per well 
of a 6-well plate (1.5 µg KIR2DL5WT, KIR2DL5CTL 
KIR2DL5N173D, shKIR2DL5 or pLKO-GFP control; 
1.5 µg lentiviral packaging constructs) using Fugene 
HD reagent (Promega) following manufacturer’s 
instructions. 24h post transfection the media was replaced 
with fresh Schwann cell media supplemented with10% 
FBS, Schwann cell growth factors and antibiotics. 
Viral preparations were collected at 48 and 72 h post-
transfection, were filtered, supplemented with polybrene 
and used for direct infections of Schwann cells. The 
sequences of the siRNA constructs were:
shKIR2DL5 #1: TCTCTCCATGACTCACCCTAT; 
shKIR2DL5 #2: CAGGAGCTCATTTGACATGTA; 
shKIR2DL5 #3: GAAACTCTTCAAGTAGTTCAT; 
KIR2DL5WT cDNA cloned in a lentiviral vector was 
purchased from Origene and was either directly transfected 
into HEK293T cells, or was transfected following site-
directed mutagenesis with QuikChange Site-Directed 
mutagenesis kit (Promega) following manufacturer’s 
instructions in order to generate KIR2DL5CTL (harboring 
six distinct base pair mutations within the short hairpin 
recognition sequences but resulting in identical 
amino acid sequence)  or KIR2DL5N173D. All resulting 
constructs were subcloned and sequenced by Genewiz. 
The following primers were used to generate the 





AGCTC-3′); KIR2DL5CTL2 (Forward: 5′- CCTACACAT 
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Figure 5: KIR2DL5A/B inhibits Schwann cell proliferation in a PDGFRβ/AKT-dependent manner.  (A) PDGFRβ is 
hyperphosphorylated following silencing of KIR2DL5 in normal human Schwann cells as demonstrated with a human phospho-RTK array. 
(B) PDGFRβTyr771 and PDGFRβTyr1009 phosphorylation is increased following KIR2DL5A/B silencing. Inhibition of aberrant PDGFRβ and 
AKT phosphorylation following 16 h imatinib (C) or sunitinib (D) treatment restores cell numbers (E) and proliferation (F) to control 
levels. Data are represented as means ± s.e.m. All experiments were repeated at least three times. Two-way ANOVA with Bonferroni 
correction was used for statistical analysis. ***p < 0.001 compared to vehicle control, p < 0.001 compared to vehicle sh#1, sh#2, sh#3, 
respectively. (G) KIR2DL5A/B silencing leads to increased PDGFRβ/PDGFRα binding, as assessed by immunoprecipitation. (H) The 
proposed model of KIR2DL5 growth regulation envisions that KIR2DL5 normally binds and sequesters PDGFRβ, such that KIR2DL5 loss 
leads to increased PDGFRα/β binding and RAS/AKT-mediated hyperproliferation.
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GCTTCGGCTCGTTACATGATTCACCGTACGAGTG 
GTCAGACCCGAGTG-3′, Reverse: 5-CACTCGG 
GTCTGACCACTCGTACGGTGAATCATGTAACGAGC 




GFP control- or siRNA-infected Schwann cells 
underwent treatment with the following reagents: MK2206 
(50nM in DMSO, 4 h; Selleckchem), rapamycin (10μM 
in DMSO, 4 h; Selleckchem), imatinib (10 μM in water, 
16h; Sigma), sunitinib (10 μM in DMSO, 16 h; Sigma), or 
PD0325901 (10 nM in DMSO, 4h; Selleckchem).
Western blotting, immunoprecipitation, RTK 
arrays and RAS/RAS pathway activity assays
Western blotting was performed on Schwann 
cells lysed in buffer containing 1% NP-40 (nonyl 
phenoxypolyethoxylethanol), supplemented with protease 
and phosphatase inhibitors using KIR2DL5 (Abcam), α–
tubulin (Sigma), RAS (Millipore), phospho-AKTThr308, 
phospho-AKTSer473, AKT, phospho-S6Ser240/244, S6, phospho-
Erk1/2Thr202/204, Erk1/2, phosphoPRAS40Thr246, PRAS40, 
phospho-PDGFRβTyr771, phospho-PDGFRβTyr1009, PDGFRβ, 
PDGFRα (Cell Signaling) primary antibodies, as well as 
HRP-conjugated secondary antibodies (Cell Signaling) 
and ECL (Fisher) chemiluminescence. Western signal band 
intensity was quantified using ImageJ Software (National 
Institutes of Health, USA, http://imagej.nih.gov/ij Java 
1.7.0_67). KIR2DL5A/BKD cell KIR2DL5 expression levels 
(Figures 2A, 3D) were calculated by normalizing the relative 
KIR2DL5/α-tubulin band intensity ratio to that of GFP-
control-infected Schwann cells. For the immunoprecipitation 
studies, 100 μg total Schwann cell protein lysate was pre-
cleared for 1h in agarose protein G beads (Cell Signaling), 
immunoprecipitated with PDGFRβ overnight and collected 
with agarose protein G beads for 2 hours.  For the human 
phospho-RTK array (human phospho-receptor tyrosine 
kinase array kit; R&D Systems) Schwann cells were lysed 
in the provided buffer and 80μg total protein was assayed 
using manufacturer’s instructions. In brief, the assay can 
detect phosphorylation of the following RTKs: ALK/
CD246, EphB4, MuSK, Axl, EphB6, PDGFRα, DDR1, 
ErbB2, PDGFRβ, DDR2, ErbB3, c-Ret, Dtk, ErbB4, ROR1, 
EGFR, FGFR1, ROR2, EphA1, FGFR2α, Ryk, EphA2, 
FGFR3, SCFR/c-kit, EphA3, FGFR4, Tie-1, EphA4, Flt-
3/Flk-2, Tie-2, EphA5, HGFR/c-MET, TrkA, EphA6, 
IGF1R, TrkB, EphA7, Insulin R/CD220, TrkC, EphA10, 
M-CSFR, VEGFR1/Flt-1, EphB1, Mer, VEGFR2/KDR, 
EphB2, MSPR/Ron, VEGFR3/Flt-4, and EphB3. Since 
only PDGFRβ was hyperphosphorylated, the activation 
was independently validated with two separate phospho-
PDGFRβ antibodies: phospho-PDGFRβTyr771, phospho-
PDGFRβTyr1009 (Cell Signaling). RAS activity assays were 
performed following Raf1-RBD immunoprecipitation using 
manufacturer’s instructions (RAS activation kit; Millipore). 
All experiments were repeated at least three times using 
independently derived cell lysates. 
Proliferation and apoptosis assays
Schwann cell proliferation and TUNEL staining 
were assessed using the BrdU Cell Proliferation 
Colorimetric ELISA kit (Roche) or the TUNEL staining 
kit (Roche) following manufacturer’s instructions. For 
both assays, Schwann cells were seeded at 5000 cells/ well 
of a 96-well plate. For the proliferation assays, Schwann 
cells were serum-starved for 24 hours, if treated, incubated 
in vehicle or appropriate inhibitors for a total of 24 hours, 
labelled with BrdU for 18 h followed by 90min incubation 
in peroxidase-conjugated anti-BrdU antibody. The optical 
density of the cells was measured at 405 nm on a Bio-
Rad spectrophotometer. For the TUNEL assay, cells were 
incubated in serum-containing media for 24 h before being 
fixed in 4% PFA, incubated in TUNEL substrate for 1 h 
and imaged using a fluorescent microscope.
Statistical analyses
All statistical tests were performed using GraphPad 
Prism 5 software. Student’s t-test, one-way or two-way 
analysis of variance (ANOVA) with Bonferroni post-test 
correction was employed for all experiments. 
Authors’ contributions
C.A., S.D., and D.H.G. designed the experiments 
and wrote the manuscript. C.A. performed the 
experiments. S.D. provided neuropathological assessments 
and tumor specimens.
ACKNOWLEDGMENTS
We appreciate the informatics advice provided 
by Drs. Mukesh Sharma and Madhurima Kaushal 
(Washington University). 
CONFLICTS OF INTEREST
The authors declare no competing financial interests.
FUNDING
This work was funded by a grant from The Giorgio 
Foundation.
REFERENCES
1. Scheithauer BW WJ, Erlandson RA. (1999). Atlas of tumor 
pathology. Tumors of the peripheral nervous system.
Oncotarget47584www.impactjournals.com/oncotarget
 2. Chen Z, Liu C, Patel AJ, Liao CP, Wang Y, Le LQ. Cells 
of origin in the embryonic nerve roots for NF1-associated 
plexiform neurofibroma. Cancer Cell. 2014; 26:695–706.
 3. Le LQ, Liu C, Shipman T, Chen Z, Suter U, Parada LF. 
Susceptible stages in Schwann cells for NF1-associated 
plexiform neurofibroma development. Cancer Res. 2011; 
71:4686–95.
 4. Le LQ, Shipman T, Burns DK, Parada LF. Cell of origin and 
microenvironment contribution for NF1-associated dermal 
neurofibromas. Cell Stem Cell. 2009; 4:453–63.
 5. Rutkowski JL, Wu K, Gutmann DH, Boyer PJ, Legius E. 
Genetic and cellular defects contributing to benign tumor 
formation in neurofibromatosis type 1. Hum Mol Genet. 
2000; 9:1059–66.
 6. Sawada S, Florell S, Purandare SM, Ota M, Stephens K, 
Viskochil D. Identification of NF1 mutations in both alleles 
of a dermal neurofibroma. Nat Genet. 1996; 14:110–2.
 7. Serra E, Puig S, Otero D, Gaona A, Kruyer H, Ars E, 
Estivill X, Lazaro C. Confirmation of a double-hit model for 
the NF1 gene in benign neurofibromas. Am J Hum Genet. 
1997; 61:512–9.
 8. Kim HA, Ling B, Ratner N. Nf1-deficient mouse Schwann 
cells are angiogenic and invasive and can be induced to 
hyperproliferate: reversion of some phenotypes by an 
inhibitor of farnesyl protein transferase. Mol Cell Biol. 
1997; 17:862–72.
 9. Kim HA, Rosenbaum T, Marchionni MA, Ratner N, 
DeClue JE. Schwann cells from neurofibromin deficient 
mice exhibit activation of p21ras, inhibition of cell 
proliferation and morphological changes. Oncogene. 1995; 
11:325–35.
10. Sherman LS, Atit R, Rosenbaum T, Cox AD, Ratner N. 
Single cell Ras-GTP analysis reveals altered Ras activity 
in a subpopulation of neurofibroma Schwann cells but not 
fibroblasts. J Biol Chem. 2000; 275:30740–5.
11. Johannessen CM, Reczek EE, James MF, Brems H, 
Legius E, Cichowski K. The NF1 tumor suppressor 
critically regulates TSC2 and mTOR. Proc Natl Acad Sci U 
S A. 2005; 102:8573–8.
12. Johansson G, Mahller YY, Collins MH, Kim MO, 
Nobukuni T, Perentesis J, Cripe TP, Lane HA, Kozma SC, 
Thomas G, Ratner N. Effective in vivo targeting of the 
mammalian target of rapamycin pathway in malignant 
peripheral nerve sheath tumors. Mol Cancer Ther. 2008; 
7:1237–45.
13. Varin J, Poulain L, Hivelin M, Nusbaum P, Hubas A, 
Laurendeau I, Lantieri L, Wolkenstein P, Vidaud M, 
Pasmant E, Chapuis N, Parfait B. Dual mTORC1/2 
inhibition induces anti-proliferative effect in NF1-associated 
plexiform neurofibroma and malignant peripheral nerve 
sheath tumor cells. Oncotarget. 2016; 7:35753–67. doi: 
10.18632/oncotarget.7099.
14. Wu J, Dombi E, Jousma E, Scott Dunn R, Lindquist D, 
Schnell BM, Kim MO, Kim A, Widemann BC, Cripe TP, 
Ratner N. Preclincial testing of sorafenib and RAD001 
in the Nf(flox/flox) ;DhhCre mouse model of plexiform 
neurofibroma using magnetic resonance imaging. Pediatr 
Blood Cancer. 2012; 58:173–80.
15. Messiaen LM, Callens T, Mortier G, Beysen D, 
Vandenbroucke I, Van Roy N, Speleman F, Paepe AD. 
Exhaustive mutation analysis of the NF1 gene allows 
identification of 95% of mutations and reveals a high 
frequency of unusual splicing defects. Hum Mutat. 2000; 
15:541–55.
16. Messiaen LM, Wimmer K. Pitfalls of automated comparative 
sequence analysis as a single platform for routine clinical 
testing for NF1. J Med Genet. 2005; 42: e25.
17. Storlazzi CT, Von Steyern FV, Domanski HA, Mandahl N, 
Mertens F. Biallelic somatic inactivation of the NF1 
gene through chromosomal translocations in a sporadic 
neurofibroma. Int J Cancer. 2005; 117:1055–7.
18. Jacoby LB, MacCollin M, Barone R, Ramesh V, 
Gusella JF. Frequency and distribution of NF2 mutations in 
schwannomas. Genes Chromosomes Cancer. 1996; 17:45–55.
19. Twist EC, Ruttledge MH, Rousseau M, Sanson M, 
Papi L, Merel P, Delattre O, Thomas G, Rouleau GA. 
The neurofibromatosis type 2 gene is inactivated in 
schwannomas. Hum Mol Genet. 1994; 3:147–51.
20. Piotrowski A, Xie J, Liu YF, Poplawski AB, Gomes AR, 
Madanecki P, Fu C, Crowley MR, Crossman DK, 
Armstrong L, Babovic-Vuksanovic D, Bergner A, 
Blakeley JO, et al. Germline loss-of-function mutations 
in LZTR1 predispose to an inherited disorder of multiple 
schwannomas. Nat Genet. 2014; 46:182–7.
21. Smith MJ, Isidor B, Beetz C, Williams SG, Bhaskar SS, 
Richer W, O’Sullivan J, Anderson B, Daly SB, Urquhart JE, 
Fryer A, Rustad CF, Mills SJ, et al. Mutations in LZTR1 
add to the complex heterogeneity of schwannomatosis. 
Neurology. 2015; 84:141–7.
22. Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-
Maandag EC, Baas F, Wesseling P. Germline mutation of 
INI1/SMARCB1 in familial schwannomatosis. Am J Hum 
Genet. 2007; 80:805–10.
23. Hutter S, Piro RM, Reuss DE, Hovestadt V, Sahm F, 
Farschtschi S, Kehrer-Sawatzki H, Wolf S, Lichter P, 
von Deimling A, Schuhmann MU, Pfister SM, Jones DT, 
et al. Whole exome sequencing reveals that the majority 
of schwannomatosis cases remain unexplained after 
excluding SMARCB1 and LZTR1 germline variants. Acta 
Neuropathol. 2014; 128:449–52.
24. Rajalingam R, Parham P, Abi-Rached L. Domain shuffling 
has been the main mechanism forming new hominoid killer 
cell Ig-like receptors. J Immunol. 2004; 172:356–69.
25. Vilches C, Rajalingam R, Uhrberg M, Gardiner CM, 
Young NT, Parham P. KIR2DL5, a novel killer-cell receptor 
with a D0-D2 configuration of Ig-like domains. J Immunol. 
2000; 164:5797–804.
26. Vilches C, Parham P. KIR: diverse, rapidly evolving 
receptors of innate and adaptive immunity. Annu Rev 
Immunol. 2002; 20:217–51.
Oncotarget47585www.impactjournals.com/oncotarget
27. Belkin D, Torkar M, Chang C, Barten R, Tolaini M, 
Haude A, Allen R, Wilson MJ, Kioussis D, Trowsdale J. 
Killer cell Ig-like receptor and leukocyte Ig-like receptor 
transgenic mice exhibit tissue- and cell-specific transgene 
expression. J Immunol. 2003; 171:3056–63.
28. Rajagopalan S, Long EO. A human histocompatibility 
leukocyte antigen (HLA)-G-specific receptor expressed on 
all natural killer cells. J Exp Med. 1999; 189:1093–100.
29. Yusa S, Catina TL, Campbell KS. KIR2DL5 can inhibit 
human NK cell activation via recruitment of Src homology 
region 2-containing protein tyrosine phosphatase-2 (SHP-
2). J Immunol. 2004; 172:7385–92.
30. Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, 
Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, 
Sabo J, Hardiman Dudley A, Niwa-Kawakita M, et al. 
MEK inhibition exhibits efficacy in human and mouse 
neurofibromatosis tumors. J Clin Invest. 2013; 123:340–7.
31. Jousma E, Rizvi TA, Wu J, Janhofer D, Dombi E, Dunn RS, 
Kim MO, Masters AR, Jones DR, Cripe TP, Ratner N. 
Preclinical assessments of the MEK inhibitor PD-0325901 
in a mouse model of Neurofibromatosis type 1. Pediatr 
Blood Cancer. 2015; 62:1709–16.
32. Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO. 
Dissecting and targeting the growth factor-dependent and 
growth factor-independent extracellular signal-regulated 
kinase pathway in human schwannoma. Cancer Res. 2008; 
68:5236–45.
33. Chen S, Burgin S, McDaniel A, Li X, Yuan J, Chen M, 
Khalaf W, Clapp DW, Yang FC. Nf1-/- Schwann cell-
conditioned medium modulates mast cell degranulation 
by c-Kit-mediated hyperactivation of phosphatidylinositol 
3-kinase. Am J Pathol. 2010; 177:3125–32.
34. Kwon YK, Bhattacharyya A, Alberta JA, Giannobile WV, 
Cheon K, Stiles CD, Pomeroy SL. Activation of ErbB2 
during wallerian degeneration of sciatic nerve. J Neurosci. 
1997; 17:8293–9.
35. Miller SJ, Li H, Rizvi TA, Huang Y, Johansson G, 
Bowersock J, Sidani A, Vitullo J, Vogel K, Parysek LM, 
DeClue JE, Ratner N. Brain lipid binding protein in 
axon-Schwann cell interactions and peripheral nerve 
tumorigenesis. Mol Cell Biol. 2003; 23:2213–24.
36. Yamauchi J, Miyamoto Y, Tanoue A, Shooter EM, Chan JR. 
Ras activation of a Rac1 exchange factor, Tiam1, mediates 
neurotrophin-3-induced Schwann cell migration. Proc Natl 
Acad Sci U S A. 2005; 102:14889–94.
37. Demestre M, Herzberg J, Holtkamp N, Hagel C, Reuss D, 
Friedrich RE, Kluwe L, Von Deimling A, Mautner VF, 
Kurtz A. Imatinib mesylate (Glivec) inhibits Schwann 
cell viability and reduces the size of human plexiform 
neurofibroma in a xenograft model. J Neurooncol. 2010; 
98:11–9.
38. Robertson KA, Nalepa G, Yang FC, Bowers DC, Ho CY, 
Hutchins GD, Croop JM, Vik TA, Denne SC, Parada LF, 
Hingtgen CM, Walsh LE, Yu M, et al. Imatinib mesylate for 
plexiform neurofibromas in patients with neurofibromatosis 
type 1: a phase 2 trial. Lancet Oncol. 2012; 13:1218–24.
39. Yang FC, Ingram DA, Chen S, Zhu Y, Yuan J, Li X, Yang X, 
Knowles S, Horn W, Li Y, Zhang S, Yang Y, Vakili ST, 
et al. Nf1-dependent tumors require a microenvironment 
containing Nf1+/— and c-kit-dependent bone marrow. Cell. 
2008; 135:437–48.
40. Aoki M, Nabeshima K, Koga K, Hamasaki M, Suzumiya J, 
Tamura K, Iwasaki H. Imatinib mesylate inhibits cell 
invasion of malignant peripheral nerve sheath tumor 
induced by platelet-derived growth factor-BB. Lab Invest. 
2007; 87:767–79.
41. Ohishi J, Aoki M, Nabeshima K, Suzumiya J, Takeuchi T, 
Ogose A, Hakozaki M, Yamashita Y, Iwasaki H. Imatinib 
mesylate inhibits cell growth of malignant peripheral nerve 
sheath tumors in vitro and in vivo through suppression of 
PDGFR-beta. BMC Cancer. 2013; 13: 224.
42. Perrone F, Da Riva L, Orsenigo M, Losa M, Jocolle G, 
Millefanti C, Pastore E, Gronchi A, Pierotti MA, Pilotti S. 
PDGFRA, PDGFRB, EGFR, and downstream signaling 
activation in malignant peripheral nerve sheath tumor. 
Neuro Oncol. 2009; 11:725–36.
43. Ferguson MJ, Rhodes SD, Jiang L, Li X, Yuan J, Yang X, 
Zhang S, Vakili ST, Territo P, Hutchins G, Yang FC, 
Ingram DA, Clapp DW, et al. Preclinical Evidence for 
the Use of Sunitinib Malate in the Treatment of Plexiform 
Neurofibromas. Pediatr Blood Cancer. 2016; 63:206–13.
